(Q53002224)

English

Humoral immune responses by prime-boost heterologous route immunizations with CTB-MPR(649-684), a mucosal subunit HIV/AIDS vaccine candidate.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

10 May 2018

http://europepmc.org/abstract/MED/16621185

Humoral immune responses by prime-boost heterologous route immunizations with CTB-MPR(649-684), a mucosal subunit HIV/AIDS vaccine candidate. (English)

1 reference

Europe PubMed Central

PubMed publication ID

10 May 2018

http://europepmc.org/abstract/MED/16621185

0 references

0 references

1 reference

based on heuristic

inferred from title

5

1 reference

Europe PubMed Central

PubMed publication ID

10 May 2018

http://europepmc.org/abstract/MED/16621185

Nobuyuki Matoba

object named as

Nobuyuki Matoba

1

0 references

author name string

Brian C Geyer

2

1 reference

Europe PubMed Central

PubMed publication ID

10 May 2018

http://europepmc.org/abstract/MED/16621185

Jacquelyn Kilbourne

3

1 reference

Europe PubMed Central

PubMed publication ID

10 May 2018

http://europepmc.org/abstract/MED/16621185

Annette Alfsen

4

1 reference

Europe PubMed Central

PubMed publication ID

10 May 2018

http://europepmc.org/abstract/MED/16621185

Tsafrir S Mor

6

1 reference

Europe PubMed Central

PubMed publication ID

10 May 2018

http://europepmc.org/abstract/MED/16621185

language of work or name

0 references

publication date

30 March 2006

1 reference

Europe PubMed Central

PubMed publication ID

10 May 2018

http://europepmc.org/abstract/MED/16621185

number of pages

9

1 reference

based on heuristic

inferred from page(s)

1 reference

Europe PubMed Central

PubMed publication ID

10 May 2018

http://europepmc.org/abstract/MED/16621185

24

1 reference

Europe PubMed Central

PubMed publication ID

10 May 2018

http://europepmc.org/abstract/MED/16621185

23

1 reference

Europe PubMed Central

PubMed publication ID

10 May 2018

http://europepmc.org/abstract/MED/16621185

5047-5055

1 reference

Europe PubMed Central

PubMed publication ID

10 May 2018

http://europepmc.org/abstract/MED/16621185

Primary intestinal epithelial cells selectively transfer R5 HIV-1 to CCR5+ cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.045

7 January 2021

Gastrointestinal tract as a major site of CD4+ T cell depletion and viral replication in SIV infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.045

7 January 2021

CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.045

7 January 2021

Primary HIV-1 infection is associated with preferential depletion of CD4+ T lymphocytes from effector sites in the gastrointestinal tract

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.045

7 January 2021

Severe CD4+ T-cell depletion in gut lymphoid tissue during primary human immunodeficiency virus type 1 infection and substantial delay in restoration following highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.045

7 January 2021

Peak SIV replication in resting memory CD4+ T cells depletes gut lamina propria CD4+ T cells.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.045

7 January 2021

Transcytosis of infectious human immunodeficiency virus across a tight human epithelial cell line barrier

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.045

7 January 2021

Mucosal and plasma IgA from HIV-1-exposed uninfected individuals inhibit HIV-1 transcytosis across human epithelial cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.045

7 January 2021

Mucosal and plasma IgA from HIV-exposed seronegative individuals neutralize a primary HIV-1 isolate

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.045

7 January 2021

Functional HIV-1 specific IgA antibodies in HIV-1 exposed, persistently IgG seronegative female sex workers

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.045

7 January 2021

Cross-Clade HIV-1–Specific Neutralizing IgA in Mucosal and Systemic Compartments of HIV-1–Exposed, Persistently Seronegative Subjects

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.045

7 January 2021

Cervicovaginal secretory antibodies to human immunodeficiency virus type 1 (HIV-1) that block viral transcytosis through tight epithelial barriers in highly exposed HIV-1-seronegative African women.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.045

7 January 2021

Transmission, acute HIV-1 infection and the quest for strategies to prevent infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.045

7 January 2021

Immunobiology of mucosal HIV infection and the basis for development of a new generation of mucosal AIDS vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.045

7 January 2021

Secretory IgA specific for a conserved epitope on gp41 envelope glycoprotein inhibits epithelial transcytosis of HIV-1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.045

7 January 2021

Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.045

7 January 2021

Anti-human immunodeficiency virus type 1 (HIV-1) antibodies 2F5 and 4E10 require surprisingly few crucial residues in the membrane-proximal external region of glycoprotein gp41 to neutralize HIV-1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.045

7 January 2021

Chemokine receptor expression in the human ectocervix: implications for infection by the human immunodeficiency virus-type I.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.045

7 January 2021

HIV-1-infected blood mononuclear cells form an integrin- and agrin-dependent viral synapse to induce efficient HIV-1 transcytosis across epithelial cell monolayer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.045

7 January 2021

Intracellular Neutralization of HIV Transcytosis across Tight Epithelial Barriers by Anti-HIV Envelope Protein dIgA or IgM

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.045

7 January 2021

High-level ability of secretory IgA to block HIV type 1 transcytosis: contrasting secretory IgA and IgG responses to glycoprotein 160.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.045

7 January 2021

Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.045

7 January 2021

Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.045

7 January 2021

A mucosally targeted subunit vaccine candidate eliciting HIV-1 transcytosis-blocking Abs.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.045

7 January 2021

Identifying epitopes of HIV-1 that induce protective antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.045

7 January 2021

Neutralizing antibody responses to HIV: role in protective immunity and challenges for vaccine design.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.045

7 January 2021

Neutralizing antibodies against HIV -- back in the major leagues?

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.045

7 January 2021

The Role of Mucosal Immunity in Prevention of HIV Transmission

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.045

7 January 2021

HIV infection and the gastrointestinal tract

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.045

7 January 2021

Mucosal AIDS vaccines: current status and future directions

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.045

7 January 2021

Mucosal-targeted AIDS vaccines: the next generation?

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.045

7 January 2021

Improvement of the systemic prime/oral boost strategy for systemic and local responses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.045

7 January 2021

Effect of homologous and heterologous prime-boost on the immune response to recombinant plague antigens

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.045

7 January 2021

Parenteral and mucosal prime-boost immunization strategies in mice with hepatitis B surface antigen and CpG DNA

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.045

7 January 2021

New generation of mucosal adjuvants for the induction of protective immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.045

7 January 2021

Mucosal immunisation and adjuvants: a brief overview of recent advances and challenges

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.045

7 January 2021

Comparison of systemic and mucosal priming for mucosal immune responses to a bacterial protein antigen given with or coupled to cholera toxin (CT) B subunit, and effects of pre-existing anti-CT immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.045

7 January 2021

Cholera toxin and its B subunit promote dendritic cell vaccination with different influences on Th1 and Th2 development

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.045

7 January 2021

Vaccine development strategies for improving immunization: the role of modern immunology

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.045

7 January 2021

A conserved tryptophan-rich motif in the membrane-proximal region of the human immunodeficiency virus type 1 gp41 ectodomain is important for Env-mediated fusion and virus infectivity.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.045

7 January 2021

based on heuristic

inferred from DOI database lookup

Role of the membrane-proximal domain in the initial stages of human immunodeficiency virus type 1 envelope glycoprotein-mediated membrane fusion.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.045

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VACCINE.2006.03.045

1 reference

Europe PubMed Central

PubMed publication ID

10 May 2018

http://europepmc.org/abstract/MED/16621185

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

10 May 2018

http://europepmc.org/abstract/MED/16621185

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53002224&oldid=1775336652"